NICE confirms Lucentis choice for wet AMD
This article was originally published in Scrip
Executive Summary
Guidance from the National Institute for health and Clinical Excellence(NICE), recommending that patients in England and Wales with wet age-related macular degeneration (AMD) receiveNovartis's Lucentis (ranibizumab, licensed from Genentech), has been confirmed after unsuccessful appeals. Pfizerwas unable to convince the institute to alter its negative assessment of Macugen (pegaptinib) in the same indication,